Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients - the BISHOP study.
Gustavo Gomes ResendeRicardo da Cruz LageSamara Quadros LobêAmanda Fonseca MedeirosAlessandra Dias Costa E SilvaAntonio Tolentino Nogueira de SáArgenil José de Assis OliveiraDenise SousaHenrique Cerqueira GuimarãesIsabella Coelho GomesRenan Pedra de SouzaRenato Santana de AguiarRoberto TunalaFrancisco Jose ForestieroJúlio Silvio de Souza Bueno FilhoMauro Martins TexeiraPublished in: Infectious diseases (London, England) (2022)
The efficacy of secukinumab in the treatment of Covid19 was not demonstrated. Secukinumab decreased pulmonary embolism in male patients. There was no difference between groups in adverse events and no unexpected events were observed.